Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin‐induced improvements in cardiometabolic health remains to be clarified. Thus, we investigated the way in which lorcaserin treatment may alter cardiovascular disease risk, either independently or through changes in body weight. We measured, for the first time, lipid particle quantification, lipid peroxidation, appetite‐regulating hormones and mRNA expression of the 5‐hydroxytryptamine 2c receptor (5‐HT2c receptor). A total of 48 obese participants were enrolled in this six‐month, randomized (1:1), placebo‐controlled, double‐blinded clinical trial. Lorcaserin treatment reduced fat mass ( P < 0.001), the fatty liver index ( P < 0.0001) and energy intake ( P < 0.03) without affecting energy expenditure or lean mass. Total low‐density lipoprotein (LDL) ( P < 0.04) and small LDL particles ( P < 0.03) decreased, while total high‐density lipoprotein (HDL) P < 0.02) increased and heart rate significantly decreased with lorcaserin treatment. No mRNA expression of the 5‐HT2c receptor was observed in peripheral organs. These data suggest that lorcaserin treatment for six months improves cardiometabolic health in obese individuals, acting mainly through the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632 · cited 1×
“therapy has often been challenging because of issues related to cardiovascular safety.(3) Conversely, it was recently demonstrated that”
BackgroundMulticenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 1×
“Despite the small number of participants, we confirmed the results of previous studies on weight and lipid outcomes in a similar population.(15) The retention rate was low, possibly because of the moderate effect on weight loss in both groups.”
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808721 · Cited by 265 · cited 1×
“5-hydroxytryptamine 2c (5-HT2c) receptor agonist, effective for longterm weight management,(4,5) is also safe, showing no increase in cardiovascular events, in addition to contributing to the prevention and remission of type 2 diabetes.(6,7) Although large clinical trials have shown an early reduction in weight-indepe…”
BackgroundBohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32328-6 · Cited by 94
Cited by
Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function
Stadler, J. T., & Marsche, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238985 · Cited by 200
Risi, R., Rossini, G., Tozzi, R., Pieralice, S., Monte, L., Masi, D., Castagneto-Gissey, L., Gallo, I. F., Strigari, L., Casella, G., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.03.022 · Cited by 68
Self-citationManagement of metabolic-associated fatty liver disease: The diabetology perspective
Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54
Metadata
- Authors
- Tuccinardi, D., Farr, O. M., Upadhyay, J., Oussaada, S. M., Mathew, H., Paschou, S. A., Perakakis, N., Koniaris, A., Kelesidis, T., & Mantzoros, C. S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-03-18
- Volume
- 21
- Issue
- 6
- Pages
- 1487-1492
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2911788056
- Cited by
- 47
- References
- 5
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial. https://app.cochat.ai/papers/10.1111/dom.13655
- The paper
- Tuccinardi, D., Farr, O. M., Upadhyay, J., Oussaada, S. M., Mathew, H., Paschou, S. A., Perakakis, N., Koniaris, A., Kelesidis, T., & Mantzoros, C. S. (2019). Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13655
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.